Invitation to presentation of Recipharm’s interim report for the first quarter on 7 May 2015

Recipharm will publish its interim report for January-March 2015 on 7 May at 07:45 am CET.

The company invites investors, analysts and media to a web conference (in English) on 7 May at 10:00 am CET, where CEO Thomas Eldered and CFO Björn Westberg will present and comment on the report as well as answer questions.

The report will be available on Recipharm’s website www.recipharm.com/en/investors from 07:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 7 May.

To participate in the web conference, please use the below link:
http://edge.media-server.com/m/p/hfsw4kpp

Questions may be submitted by dialing below telephone numbers or by typing them in the Q&A box during the conference. If you don’t wish to ask questions by telephone you only need to participate through the link above.

From Sweden: + 46 8 505 56 453
From Denmark: + 45 35 44 55 74
From Finland: + 358 9 8171 0490
From Norway: + 47 235 00 251
From the UK: + 44 203 009 24 55
From Germany: +49 211 971 900 76
From Switzerland: +41 225 80 29 94
From France: + 33 170750706
From Spain: +34 911 140 089
From Portugal: +35 121 06 09 104 
From USA: +1 855 228 3719 

Pin code for participants:
213122#

For more information, please contact:
Björn Westberg, CFO, +46 8 602 46 20, ir@recipharm.com

For questions about participation in the event, please contact:
Linda Holmström, Brand & Communications Manager, + 46 8 602 45 13, linda.holmstrom@recipharm.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links